TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02306902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: 130mg, Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTARA® (fenofibrate)
Description: 130mg, Capsules
Study: NCT04287296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wakey!
Description: Everyone who has downloaded the app will receive a 9-minute morning show as an alternative to an alarm clock every Mon-Fri for 12 weeks. The show is presented by a cast of presenters who appeal to the target demographic. The intervention content is theory and evidence led, drawing on approaches from cognitive and third-wave psychotherapies, positive psychology interventions (such as those based on resilience training and growth mindset), and lifestyle mental health interventions. Additional content will be provided on the app to support the theory and techniques that are covered in the show. Fun content will also be posted in an ad-hoc manner that complement the shows or relate to cultural dates and aim to increase engagement. Wakey! will avoid any polarising topics such as politics, religion and folk science. There are several features beside the show itself: a moderated live chat between 6-9AM, feedback for users (e.g. how many days they have seen the show, current energy levels).
Study: NCT01657240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118
Description: instill one drop in each eye once a day for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride
Description: instill one drop in each eye once a day for 21 days
Study: NCT02136069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: 105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (IV)
Description: Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Injection)
Description: Administered by SC injection Q4W until Week 52
Study: NCT02350296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSL 40 mg
Description: Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSL 40 mg
Description: Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKi® 80 mg
Description: OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKi® 80 mg
Description: OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
Study: NCT02961829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: antiretroviral intensification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: antiretroviral intensification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: antiretroviral intensification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: antiretroviral intensification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: antiretroviral intensification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: antiretroviral intensification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: antiretroviral intensification

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: antiretroviral intensification

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Therapeutic vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Therapeutic vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: purging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: purging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirtuin Histone deacetylase inhibitor
Description: latency disruption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirtuin Histone deacetylase inhibitor
Description: latency disruption
Study: NCT02299843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RALPPS
Description: Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALPPS
Description: Treat the hepatocellular carcinoma with ALPPS.
Study: NCT03972943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Receive CPAP treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01281800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gemcitabine in long infusion
Description: TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine in long infusion
Description: TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy.
Study: NCT04733859

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: subjects drank 50 ml , 1 bottle a day for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red djulis drinks
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study: NCT03110770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VRC-PBSPLA043-00-VP
Description: A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
Study: NCT03458195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bio-banking collection
Description: blood samples, biopsies, and surgical specimen collected in addition to usual practice
Study: NCT04106206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01179113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
Study: NCT03879005

Intervention type: OTHER
Group type: OTHER
Intervention: renal scintigraphy
Description: 99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each.
Study: NCT00419952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (SYMBICORT) pMDI
Description: Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide HFA pMDI
Description: Budesonide HFA pMDI 160 ug x 2 actuations BID
Study: NCT02877589

Intervention type: OTHER
Intervention: hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)
Study: NCT01666041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate/omega

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Study: NCT02590224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous bis-glycinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous glycine sulphate
Study: NCT02549365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surveillance (nasal swabbing) during influenza season

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surveillance (nasal swabbing) during influenza season
Study: NCT03212781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron dextran
Description: total dose infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate
Description: oral tablets
Study: NCT04301804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: a selective small-molecule CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: a selective small-molecule CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: a selective small-molecule CDK4/6 inhibitor
Study: NCT01662609

Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound (EUS)
Description: Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
Study: NCT01963078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04873219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manufacturing a complete dental prosthesis
Description: dental treatment to replace missing teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manufacturing a complete dental prosthesis
Description: dental treatment to replace missing teeth
Study: NCT00586417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: punch biopsy
Description: skin biopsies
Study: NCT03031015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cemented K-wire Fixation
Description: Fractures were reduced and then fixed with cemented K-wires.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented K-wire Fixation
Description: Fractures were reduced and then fixed with cemented K-wires.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plating
Description: Fractures were reduced and then fixed with Plate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plating
Description: Fractures were reduced and then fixed with Plate.
Study: NCT00934362

Intervention type: DRUG
Group type: OTHER
Intervention: Lucinactant first
Description: lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo first
Description: 6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
Study: NCT03917953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3).
Study: NCT04239391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Ferric Pyrophosphate Citrate
Study: NCT01278212

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated hypofractionated radiotherapy (AHF-RT)
Description: 30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
Study: NCT02835976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olesoxime
Description: Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
Study: NCT00946621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg Capsule (Sandoz)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
Study: NCT02295670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vividtrac
Description: video-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vividtrac
Description: video-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct-laryngoscopy
Study: NCT04462614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decrease per-dialytic heparin therapy
Description: Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
Study: NCT05911685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeaLA™ left atrial appendage occluder
Description: 1. Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~2. Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~3. Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~4. Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage.
Study: NCT02296645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.
Study: NCT03048578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda
Description: Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Saline Solution
Study: NCT02861001

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional bronchoscopy
Description: optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight-SL tube
Description: optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
Study: NCT03777891

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: phonophoresis with different material
Description: phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: phonophoresis with different material
Description: phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: phonophoresis with different material
Description: phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
Study: NCT04518267

Intervention type: BEHAVIORAL
Intervention: Structured clinical interview
Description: A structured clinical interview will be performed at enrollment.

Intervention type: BEHAVIORAL
Intervention: Structured clinical interview
Description: A structured clinical interview will be performed at enrollment.

Intervention type: BEHAVIORAL
Intervention: Psychological questionnaires
Description: Several psychological questionnaires will be performed at enrollment.

Intervention type: BEHAVIORAL
Intervention: Psychological questionnaires
Description: Several psychological questionnaires will be performed at enrollment.
Study: NCT03898557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of HIV self-test with Commitment and planning prompts
Description: The interventions will use behavioral interventions such as commitment and planning prompts to increase the update of HIV self-testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of HIV self-test
Description: This arm will receive a HIV self-test